NCT03765671View on ClinicalTrials.gov

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

June 7, 2019

Study Completion Date

June 14, 2019

Conditions

Hepatic ImpairmentLiver DiseasePharmacokinetics

Interventions

DRUG

Elafibranor

120mg oral single dose

Trial Locations (2)

33136

Division of Clinical Pharmacology, University of Miami, Miami

inVentiv Health Clinical Research, Miami

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Syneos Health

OTHER

collaborator

University of Miami

OTHER

lead

Genfit

INDUSTRY